Erika Hernández, Senior Oncology Medical Manager at AstraZeneca, shared a post on LinkedIn:
“Historic results in EGFRm advanced lung cancer
At the IASLC World Conference on Lung Cancer (WCLC 2025) in Barcelona, David Planchard presented the final overall survival (OS) results from the FLAURA2 trial, evaluating osimertinib + chemotherapy versus osimertinib monotherapy as first-line treatment for patients with EGFR-mutated advanced NSCLC.
Key findings:
• Median OS: 47.5 months with the combination vs 37.6 months with monotherapy.
• 23% reduction in the risk of death (HR 0.77; 95% CI 0.61–0.96; p=0.02).
• 4-year OS rates: 49% with the combination vs 41% with monotherapy.
• Progression-free survival (PFS) also demonstrated significant and clinically meaningful improvement, consistent across predefined subgroups.
• OS benefit observed despite subsequent therapies received in both arms.
Safety and tolerability:
• Safety profile consistent with expectations.
• No new safety signals identified.
• Adverse events were manageable and in line with osimertinib + chemotherapy use.
Clinical impact:
These results position osimertinib + chemotherapy as a new first-line standard of care for patients with EGFR-mutated advanced NSCLC, delivering a significant OS improvement compared to monotherapy.”